Covid19 – Africa drops plans of buying vaccine from India
The Oxford-AstraZeneca vaccine, codenamed AZD1222 and sold by the Serum Institute under the brand name ‘Covishield’, has been facing concern from experts worldwide after a few rare blood clotting-events were reported in several European countries.
Raji Tajudeen, head of Division of Public Health Institutes and Research, told Anadolu Agency that the health agency will get entire vaccines from Johnson & Johnson. “As Africa CDC we will be partnering with J&J,” he said. But he added that the UN-led COVAX facility, a global initiative aimed at equitable access to COVID-19 vaccines, would be providing vaccines produced by the institute.
The statement comes the day after European and British medicine regulators said they had found possible links between AstraZeneca’s vaccine and reports of very rare cases of brain blood clots, but they reaffirmed its importance in protecting people.
The COVAX scheme is designed to get vaccine supplies to less wealthy countries. The WHO last month published a list of the first vaccine allocations under the project.